https://www.optimumcomms.com/wp-content/uploads/2023/07/Template_Logo_300x180px-80x80Web_Logos-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg
Healthcare Team2023-08-29 08:46:212023-08-29 08:46:21Lytix Biopharma announces completion of patient recruitment in the ATLAS-IT-05 trial
https://www.optimumcomms.com/wp-content/uploads/2023/06/Vicore_Pharma_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg
Healthcare Team2023-08-24 09:15:272023-08-24 09:15:27Vicore Pharma: Interim Report April-June 2023
https://www.optimumcomms.com/wp-content/uploads/2023/06/Vicore_Pharma_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg
Healthcare Team2023-08-22 08:49:412023-08-22 08:49:41Vicore reports data from EndoPAT® exploratory trial
https://www.optimumcomms.com/wp-content/uploads/2023/06/Calliditas_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg
Healthcare Team2023-08-17 10:07:592023-08-17 10:07:59Interim Report Q2, 2023
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg
Healthcare Team2023-08-17 08:41:012023-08-17 08:41:01Novo Holdings participates in $290m strategic financing of Sangon Biotech
https://www.optimumcomms.com/wp-content/uploads/2023/06/Calliditas_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg
Healthcare Team2023-08-15 16:01:232023-08-15 16:01:23Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet
https://www.optimumcomms.com/wp-content/uploads/2023/07/IO-Biotech.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg
Healthcare Team2023-08-11 13:36:372023-08-11 13:36:37IO Biotech Announces 2023 Second Quarter Results
https://www.optimumcomms.com/wp-content/uploads/2023/07/IO-Biotech.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg
Healthcare Team2023-08-11 13:07:442023-08-11 13:07:44IO Biotech Appoints Heidi Hunter to its Board of Directors
https://www.optimumcomms.com/wp-content/uploads/2023/07/Template_Logo_300x180px-80x80Web_Logos-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg
Healthcare Team2023-08-11 08:30:492023-08-11 09:58:04Lytix Biopharma’s licensing partner Verrica Pharmaceuticals Inc. reports interim Phase II data with LTX-315
https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg
Healthcare Team2023-08-10 08:27:392023-08-10 08:27:394SC provides Q2 2023 and H1 2023 update
https://www.optimumcomms.com/wp-content/uploads/2023/02/StormTx_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg
Healthcare Team2023-08-09 08:41:162023-08-09 08:41:16STORM Therapeutics to present the discovery of lead clinical candidate STC-15 at the American Chemical Society Fall 2023 Conference
https://www.optimumcomms.com/wp-content/uploads/2023/08/Rejuvenate_-Biomed_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg
Healthcare Team2023-08-09 08:35:312023-08-09 08:37:10Rejuvenate Biomed announces publication of data showing that RJx-01 significantly increases muscle mass, muscle strength and physical performance in sarcopenia mouse models
https://www.optimumcomms.com/wp-content/uploads/2023/02/FM_Logo_300px.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg
Healthcare Team2023-08-09 07:51:572023-08-09 07:51:57Futura Medical – MED3000 approved for Commercialisation in Saudi Arabia under the brand name Eroxon®
https://www.optimumcomms.com/wp-content/uploads/2023/07/IO-Biotech.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg
Healthcare Team2023-08-08 13:12:042023-08-08 13:12:04IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg
Healthcare Team2023-08-08 08:51:522023-08-08 08:51:52Novo Holdings participates in EUR 30 million Series A financing of Bactolife, a Danish biotech company dedicated to strengthening the gut microbiome and fighting antimicrobial resistance
https://www.optimumcomms.com/wp-content/uploads/2023/02/StormTx_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg
Healthcare Team2023-08-08 08:44:382023-08-08 08:44:38STORM Therapeutics publishes data in Cancer Discovery showing induction of anti-tumour immunity by METTL3 inhibition
https://www.optimumcomms.com/wp-content/uploads/2023/07/IO-Biotech.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg
Healthcare Team2023-08-07 13:30:112023-08-07 13:41:29IO Biotech, Inc. Announces $75 Million Private Placement Financing
https://www.optimumcomms.com/wp-content/uploads/2023/02/Biocomposites_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg
Healthcare Team2023-08-02 09:56:122023-08-02 09:56:12Biocomposites appoints two new Directors to strengthen its team for its next phase of growth
https://www.optimumcomms.com/wp-content/uploads/2023/02/Neuraxpharm_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg
Healthcare Team2023-08-01 12:04:182023-08-01 12:04:18TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy)
https://www.optimumcomms.com/wp-content/uploads/2023/08/Invizius_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2022/08/Optimum_Logo_Build.svg
Healthcare Team2023-08-01 09:16:052023-08-01 09:16:05Invizius receives MHRA approval to commence First-in-Human clinical study of H-Guard® Priming SolutionFor more information about Optimum Strategic Communications, please get in touch.
